Title and Organization:
J. Joseph Kim, Ph.D., is co-founder and CEO of Inovio, a biotechnology company leading the world in developing immunotherapies, medicines that train body’s immune system to attack a broad array of cancers and challenging infectious diseases such as influenza, Ebola, and HIV/AIDS. He previously developed vaccines for Merck & Co. An immunologist by training, Joseph holds an MIT undergraduate degree, a PhD in biochemical engineering from the University of Pennsylvania, and an MBA from Wharton. He has published more than 100 scientific papers, holds numerous patents, and sits on editorial boards and scientific review panels. In 2015 Dr. Kim was named Entrepreneur of the Year for Life Sciences by Ernst and Young in Philadelphia region. He serves on the board of the International Vaccine Institute. The World Economic Forum selected Dr. Kim as a member of its Global Agenda Council and named him a “Technology Pioneer.” The Forum also selected him as one of its Young Global Leaders, one of 175 executives chosen from 50 countries. MIT’s Technology Review magazine called him "one of the world’s top innovators." Joseph is a Fellow of the inaugural class of the Health Innovators Fellowship and a member of the Aspen Global Leadership Network.